CATT Study Chair Discusses Five-Year Update (Video)
Daniel F. Martin, MD, Chair, Cole Eye Institute, discusses key five-year findings from the Comparison of AMD Treatments Trials (CATT) study at ARVO 2016.
Five year results from the Comparison of AMD Treatments Trials (CATT) study are nothing short of “remarkable,” says Daniel F. Martin, MD, chair of the study and of Cleveland Clinic’s Cole Eye Institute. This landmark clinical trial of nearly 650 patients found that, although vision gained during the first two years of treatment was not maintained, nearly half of patients still could see 20/40 or better after five years of treatment. Fifteen years ago, before the availability of anti-VEGF therapy, there was a high probability that almost all of these patients would be legally blind by five years, with most of them legally blind within two years.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
In this video, Dr. Martin discusses key five-year findings from CATT at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in May 2016. Rahul N. Khurana, MD, editor-in-chief of the Ophthalmic News and Education Network, interviews.
Read the full study in Ophthalmology.